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HAARTThe main impediment to a cure for HIV is the existence of long-lasting treatment resistant viral reservoirs. In
this review, we discuss what is currently known about reservoirs, including their formation andmaintenance,
while focusing on latently infected CD4+ T cells. In addition, we compare several different in vivo and in vitro
models of latency. We comment on how each model may reﬂect the properties of reservoirs in vivo, especially
with regard to cell phenotype, since recent studies demonstrate that multiple CD4+ T cell subsets contribute
to HIV reservoirs and that with HAART and disease progression the relative contribution of different subsets
may change. Finally, we focus on the direct infection of resting CD4+ T cells as a source of reservoir formation
and as a model of latency, since recent results help explain the misconception that resting CD4+ T cells
appeared to be resistant to HIV in vitro.ding, 3620 Hamilton Walk, Philadelphia, PA 19104, USA.
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Fig. 1. Continuum of Latency. Several types of post-integration latency may exist. Some
latently infected cells may contain integrated DNAwithout transcribing viral RNA (top).
Other cells may transcribe viral RNA, but not may translate viral proteins (second from
top). Finally, some latent cells may produce viral proteins but not infectious virions
(second from bottom). Cells are no longer latent when they produce virions, as is the
case in activated CD4+ T cells (bottom).
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The widespread introduction of highly active anti-retroviral
therapy (HAART) in the U.S. in 1995 led to impressive decreases in
HIV-related morbidity andmortality (El-Sadr et al., 2006; Gulick et al.,
1997; Hammer et al., 1997; Harrison et al., 2010; Palella et al., 1998).
However, treated patients must still endure the side effects of HAART
and the stigma of HIV infection. Furthermore, lifelong antiretroviral
therapy is costly and not available to everyone. Thus, curing HIV is still
an important goal.
In the late 1990s, the concept of treatment resistant HIV reservoirs
and latent infection of resting CD4+ T cells arose out of both clinical
and basic research ﬁndings. Clinically, it was noted that HIV+ patients
who were treated with HAART for several years (Palmer et al., 2008)
were not cured: even though these patients had undetectable viral
loads by standard assays, viremia recurred within a few weeks of
stopping HAART (Chun et al., 2000; Davey et al., 1999; Imamichi et al.,
2001; Rosenberg et al., 2000; Zhang et al., 2000). Concurrently,
pioneering basic research demonstrated that a subset of resting CD4+
T cells from HIV infected individuals on HAART contained integrated
HIV DNA (~1 integrated copy of HIV in 10,000 CD4+ T cells), but did
not produce infectious virions (Chun et al., 1997a; Chun et al., 1995;
Chun et al., 1997b); however, if these cells were stimulated, only a
fraction released infectious virus (~1 integrated copy capable of
producing infectious virus existed in 1 million CD4+ T cells) (Finzi
et al., 1997). These few cells capable of producing infectious virions
are thought to replenish the viral load back to the levels that were
present before treatment was initiated (Dahl and Palmer, 2009;
Lassen et al., 2004a,b; Pierson et al., 2000b). There are several
consequences of reservoir formation beyond creating treatment
resistant sources of virus, including the ability to archive drug
resistant virus (Nettles et al., 2005; Persaud et al., 2004). Once a
drug resistant virus forms, the virus can be archived in the reservoir
and so last for the lifetime of the patient. These observations
emphasized the need to study this treatment resistant reservoir. For
the purposes of this review we will only consider latently infected
CD4+ T cells, since they (1) are the most infected cell type in the HIV
reservoir (2) are the best deﬁned component of the reservoir (3) have
been studied in the greatest depth and (4) are the longest lived of the
known reservoirs.
Deﬁning latently infected cells (Fig. 1)
Latently infected cells are classically deﬁned as cells that contain
integrated HIV DNA and are transcriptionally silent, but upon
activation are capable of producing infectious virus. It is intuitive to
assume that latently infected cells do not transcribe HIV RNA or
express HIV proteins. However, there is evidence to the contrary.
Speciﬁcally, resting CD4+ T cells from HAART treated patients do
have low levels of HIV RNA (Lassen et al., 2004b; Lassen et al., 2006; Li
et al., 2005; Zhang et al., 1999), as do PBMC from patients on HAART
(Fischer et al., 2008; Hockett et al., 1999; Pasternak et al., 2009).
Whether this level is sufﬁcient for signiﬁcant protein expression is
unclear, as the levels of HIV RNA are lower than in activated CD4+
T cells (Lassen et al., 2004b; Zhang et al., 1999; Zhang et al., 2004).
There are also important qualitative differences in HIV transcripts in
resting and activated CD4+ T cells. While abortive transcripts are
prominent, unspliced RNA forms are detected routinely and spliced
forms are detected less frequently in resting CD4+ T cells (Lassen
et al., 2004b).
It is possible that the HIV RNA detected in resting CD4+ T cells
comes from cells that have just returned from an activated state and
therefore does not represent HIV RNA transcription in latently
infected cells; it may also represent cells that have recently been
stimulated, but have not yet upregulated activation markers (Arlen
et al., 2006; Lassen et al., 2004b; Lassen et al., 2006; Li et al., 2005;Zhang et al., 1999). Alternatively, there may be a continuum of
latency, from latently infected cells that do not transcribe HIV RNA to
cells that produce HIV proteins but not infectious virus (Fig. 1). In
other words, there may be different barriers to productive infection in
different populations of latently infected cells. For example, low-level
p24 production is detectable in latent cell models, including direct
inoculation of resting CD4+ T cells (Brooks et al., 2003b; Plesa et al.,
2007; Selliah et al., 2006). It is important to determine if latently
infected cells are capable of expressing HIV proteins because this
would suggest that the infected cells could be targets of effective
cytotoxic T lymphocytes or other immune responses.
Composition of the reservoir
There are several components of the latent HIV reservoir,
evidenced by the four phases of decay seen in plasma viremia after
the initiation of HAART therapy (Ho et al., 1995; Palmer et al., 2008;
Wei et al., 1995). These different phases represent the decay of
different cell populations with different half-lives (Palmer et al.,
2008). CD4+ T cells are the predominant latently infected cells (see
below), and these cells can be broken down into several subsets
Table 1
Proportion of latently infected cells across different cohorts.
Intergrated HIV
DNA (copies per
million CD4+ T)
IUPM (copies per
million CD4+ T)
Estimated proportion of g
integrated HIV capable of
producing infectious virus
Chronic
progressors
1000 (b16–4600)a 20 (2–400)d 0.02
Chronic on
HAART
100 (43–1000)b 1 (0.32–3.25)e 0.01
Elite
suppresors
20 (1–185)c b0.02 (b0.02–0.02)f b0.0005
Extracted from: a Yu et al., 2008, Chun et al., 1997a,b b Agosto et al., 2011, Yu et al., 2008,
Chomont et al., 2009 c Graf et al., 2011 d Chun et al., 1997a,b e Strain et al., 2005; Gandhi
et al., 2009; Dinoso et al., 2009a,b; Shen et al., 2003 f Blankson et al., 2007.
g Calculated by dividing extrapolations of IUPM by integrated HIV DNA.
Levels of integrated HIV DNA and infectious units per million CD4+ T cell were
estimated for each cohort based on weighted medians from values reported in the
literature cited. Notably IUPM measurements were made in different patients that
integrated HIV DNA, therefore small differences in the ratio of IUPM/integrated HIV
should not be considered signiﬁcant. All values were rounded to one signiﬁcant ﬁgure
and the ranges reported are indicated in parentheses.
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memory, and terminally differentiated cells (Chomont et al., 2009).
Recent studies by Chomont et al. have revealed the HIV reservoir is
located in several of these subsets, including central memory,
transitional memory, effector memory, and naïve cells (Chomont
et al., 2009). The majority of the reservoir is located in the central
memory and transitional memory subsets (Chomont et al., 2009).
While memory cells contain larger amounts of HIV DNA in patients on
HAART, total HIV DNA has been found to decline in memory cells,
while remaining constant in naïve cells (Wightman et al., 2010). This
may be a result of the death of memory cells due to immune activation
or differentiation into shorter-lived subsets and may indicate that
naïve cell infection may play a larger role in the HIV reservoir over
time. Therefore, it is important to be able to study latency in each of
these subsets without affecting their phenotype.
Additionally, evidence has accumulated suggesting that reservoirs
other than latently infected CD4+T cells also exist (Coiras et al., 2009;
Dahl and Palmer, 2009). Some of this evidence comes from
sequencing virus in the plasma and ﬁnding that prominent clonal
viral sequences are often not detected among CD4+ T cells in the
blood (Bailey et al., 2006; Brennan et al., 2009). Treatment resistant
virus may persist in macrophages (Igarashi et al., 2001) or perhaps
stem cells or progenitor cells (Carter et al., 2010). Notably, macro-
phages could contribute to reservoirs since infection of these cells is
detected in vivo (Zhang et al., 1999), especially when T cells are
depleted (Igarashi et al., 2001) and these cells seem to have extended
lifespans upon infection (Igarashi et al., 2001; Redel et al., 2010;
Swingler et al., 2007). Additionally, macrophages have been shown to
be capable of transmitting virus to lymphocytes six weeks after
blocking ongoing replication in vitro (Sharova et al., 2005). Dendritic
cells and monocytes, which have been shown to be infected to some
extent in vivo (Donaghy et al., 2001; Ellery et al., 2007; Jaworowski
et al., 2007; Lambotte et al., 2000; McIlroy et al., 1995; Otero et al.,
2003; Sonza et al., 2001; Zhu et al., 2002), are unlikely to contribute to
reservoirs directly because of their short half-lives (Kamath et al.,
2002; Liu et al., 2009; Liu et al., 2007; O'Keeffe et al., 2002; Whitelaw,
1972). However, monocytes may contribute indirectly by differenti-
ating into a longer-lived macrophage after migrating into the CNS, for
example (Burdo et al., 2010; Hasegawa et al., 2009).
Resting CD4+ T cells, the major contributor to the reservoir
Latently infected resting CD4+ T cells were ﬁrst described by the
Siliciano lab in 1995 (Chun et al., 1995). These cells are resting CD4+
T cells that lack activationmarkers including CD69, CD25, and HLA-DR
(Han et al., 2007). Resting CD4+T cells are in the G0/1a stage of the cell
cycle, express limited levels of the transcription factors NFAT and NF-
κβ, and have limited pools of deoxynucleosides, which are important
for the efﬁcient expression of the HIV LTR (Colin and Van Lint, 2009;
Dahl and Palmer, 2009; Margolis, 2010). In addition, resting cells have
been shown to be enriched for microRNAs involved in HIV latency
(Huang et al., 2007). Studies from Haase's laboratory have shown that
CD4+ T cells are the most frequently infected cells on and off HAART
(Li et al., 2005; Schacker et al., 2000; Zhang et al., 1999; Zhang et al.,
2004). Furthermore, during acute infection, when reservoirs form,
resting CD4+ T cells are the most prominently infected cell type (Li
et al., 2005; Zhang et al., 2004). Latently infected resting CD4+ T cells
have been further characterized in a large number of papers as
reviewed (Bosque and Planelles, 2011; Coiras et al., 2009; Colin and
Van Lint, 2009; Dahl et al., 2010; Han et al., 2007; Lassen et al., 2004a,
b; Vatakis et al., 2010). Additionally, eradicating latently infected T
cells (and possibly stem cells) may be enough to prevent virus
rebound after cessation of therapy. Evidence for this is made clear in
the case of the bone marrow transplant patient who received stem
cells from a CCR5 negative donor after a nonmyeloablative regimen
(Hutter et al., 2009). CCR5 positive macrophages were identiﬁed posttransplant, yet virus was never detected. This suggests, in this one
patient, that macrophage infection did not play a large role in viral
persistence and that eliminating latently infected CD4+ T cells
prevented viral rebound. Thus, CD4+ T cells are an important
component of the reservoir.Assays to measure reservoirs (Table 1)
Because the latent reservoir is a barrier to a cure for HIV,
measuring the size of the reservoir becomes paramount. The assay
designed to measure latently infected cells is called the Infectious
Units Per Million (IUPM) assay, which was developed by Siliciano and
Wong's groups (Finzi et al., 1997; Wong et al., 1997). In this assay,
resting CD4+ T cells from an HIV infected individual on HAART are
diluted serially and then activated in the presence of many allogeneic
susceptible T blasts as targets to allow spreading infection (Siliciano
and Siliciano, 2005). By counting the number of wells positive for
spreading infection under limiting dilution conditions, it is possible to
determine the number of latently infected cells. By this assay, latently
infected cells can be deﬁned as cells that contain HIV DNA but do not
produce infectious virions until they are stimulated to enter the cell
cycle. More vigorously, this assay can be used to deﬁne latent cells as
cells containing integrated DNA that do not release virions until
stimulated if steps are taken to remove pre-integration complexes
(Lassen et al., 2004a,b) as described (Chun et al., 1997a). The IUPM
assay has been very useful for characterizing reservoir cells, but is very
laborious and costly.
Measurements of integrated HIV DNA may be a useful surrogate
marker of latently infected cells (Brussel et al., 2005; Liszewski et al.,
2009; Richman et al., 2009). It is estimated that ~1 in 100 integrated
copies are capable of productive infection, although it is unclear if the
fraction of replication competent virus is constant from patient to
patient (Chun et al., 1997a). However, studies that have measured
latently infected cells over time show a constant level of both IUPM
and integrated HIV DNA, suggesting that changes in the levels of
integrated HIV DNA would be a good surrogate marker for changes in
reservoir size (Brussel et al., 2003; Chomont et al., 2009; Finzi et al.,
1997; Koelsch et al., 2008; Siliciano et al., 2003). There are some cases
where measuring integrated DNA may be preferable to measuring
IUPM. For example, the levels of latently infected cells are so low in
elite suppressors (ES) that the level is often below the detection limit
of the IUPM assay (Blankson et al., 2007; Julg et al., 2010). On the
other hand, in one study integration was detectable in 10 out of 10 ES
individuals (Graf et al., 2011). Thus, the integration assay appears to
be both more sensitive and easier to perform than the IUPM assay.
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infected cells, it is important to consider that a large fraction of
integrated HIV proviruses are defective and contain a large number of
mutations (Sanchez et al., 1997; Vartanian et al., 1992). It is unclear
whether it is possible to clear cells containing defective HIV.
Theoretically, cells that contain defective proviruses that cannot be
transcribed should be invisible to the immune system and anti-
retroviral therapies. If such cells exist among the central memory
population that homeostatically proliferates, it may be impossible to
eradicate all HIV DNA from an individual, even though it might be
possible to eliminate all sources of infectious virus. Therefore, while
integrated DNA is a more sensitive measurement, the IUPM assay
would best determine if any cells are capable of producing viable HIV
particles. Importantly, measuring both integration levels and IUPM
levels was critically important to characterize the T cell reservoir in
HIV infection (Pierson et al., 2000b).
Size of the HIV reservoir based on IUPM compared to integration
levels (Table 1)
The Siliciano group used the IUPM assay to follow the size of the
reservoir over many years (Siliciano et al., 2003). Interestingly, the
size of the reservoir does not change much over time on HAART and
each individual appears to have their own set level of latently infected
cells (Siliciano et al., 2003) and level of integrated HIV DNA in CD4+
T cells ((Chomont et al., 2009; Koelsch et al., 2008) and our
unpublished observations). Table 1 summarizes measurements of
integration and IUPM in the literature. The average reservoir size in a
patient on HAART is about 1 latently infected CD4+ T cell per million
CD4+ T cells (Gandhi et al., 2009; Strain et al., 2005). It is about 1 log
higher in patients off HAART (Chun et al., 1997a) and much higher
during acute infection (Blankson et al., 2000). (The estimates of IUPM
in acute infection may be over-estimates as pre-integration com-
plexeswere not prevented from contributing to the signal). The size of
the reservoir is unknown in ES because the level is below detection
limits in several cases. Nevertheless, we can conclude it is at least 50
times lower than in HAART patients (Table 1). Interestingly, the ratio
of IUPM per integrated DNA is similar in chronic progressors on or off
HAART (~.01), but is much lower for ES patients (Table 1). This
suggests that ES may have more defective proviruses than the other
groups or may indicate that cytotoxic T lymphocytes or other immune
pressures may clear latently infected cells that express HIV proteins in
ES. This seems reasonable given that ES patients appear to have more
potent CTL activity than the other categories of HIV infected
individuals (Migueles et al., 2008; O'Connell et al., 2009).
Mechanisms of reservoir formation
How the reservoir is initially formed is an open question. Latently
infected CD4+ T cells may arise from activated CD4+ T cells that
return to a resting state after becoming infected (Han et al., 2007).
This idea is supported both by the fact that memory cells contribute
the most to latently infected CD4+ T cells (Chun et al., 1995; Chun et
al., 1997a) and that activated cells are infectedmore efﬁciently in vitro
than resting CD4+ T cells (Stevenson et al., 1990; Zack et al., 1990).
However, the fact that resting cells are the prominently infected cells
early in infection (Li et al., 2005) when reservoirs are forming (Chun
et al., 1998) suggests that direct infection of resting CD4+ T cells may
also be a mechanism for reservoir formation. This idea is now
supported by in vitro data showing direct infection of resting cells can
occur (Agosto et al., 2007; Dai et al., 2009; Hladik et al., 2007; Plesa
et al., 2007; Swiggard et al., 2005; Vatakis et al., 2007). Additionally, a
cytokine rich environment (Eckstein et al., 2001; Kinter et al., 2003)
and the presence of DCs (Haase, 2005; Wu and KewalRamani, 2006)
and macrophages (Swingler et al., 2003) may enhance reservoir
formation by this mechanism as discussed below (under models). It isdifﬁcult to determine the extent that these two mechanisms of
reservoir formation occur in vivo, particularly since the HIV reservoir
may form differently in different patients. Two groups attempted to
address this issue by sequencing the integration sites after direct
inoculation of resting and activated T cells in vitro (Brady et al., 2009;
Vatakis et al., 2009) and to compare this to the integration sites in vivo.
However, the differences in the integration sites between resting and
activated CD4+ T cells were barely detectable. Thus it would be
difﬁcult to identify if latent cells were infectedwhile theywere resting
or activated based on sites of HIV integration.
Mechanisms of reservoir persistence
The average HIV reservoir half-life is 44 months (Finzi et al., 1997;
Siliciano et al., 2003). Because of this long half-life, important
questions have arisen regarding how the reservoir is maintained.
The most accepted theory on how the viral reservoir persists is that
long-lived cells, such as central memory cells, are infected early and
persist for the lifetime of the patient, potentially by homeostatic
proliferation (Dahl and Palmer, 2009; Shen and Siliciano, 2008).
Central memory cells have an intermitotic half-life of about 3–
6 months in uninfected individuals (McLean andMichie, 1995; Michie
et al., 1992) and shorter still in HIV infected individuals (Hellerstein
et al., 2003), and so central memory cells should divide several times
within a year. A potential problem with this theory is that it seems
likely that when the memory cell enters the cell cycle, HIV expression
would be induced, which would lead to viral toxicity. However, it is
possible that only minimal HIV expression occurs as these memory
cells proliferate. Several arguments support this theory of persistence
including the previously mentioned constant level of latently infected
cells over time as assessed by IUPM and integration.
An alternate theory is that very low levels of ongoing replication
refuel the reservoir (Dahl and Palmer, 2009; Shen and Siliciano, 2008).
The fact that circular forms of HIV DNA increase (Buzon et al., 2009)
upon addition of integrase inhibitors is consistent with the idea that
ongoing replication occurs, as recent reverse transcripts would need
to be present to form new circles. Additional evidence includes that
viral RNA in the ileum and cellular activation decreases with integrase
inhibitors (Yukl et al., 2010), that activated CD4+ T cells have higher
levels of DNA than resting CD4+ T cells in patients on HAART (Chun
et al., 2005), and that the apparent in vivo half-life of unintegrated HIV
DNA is greater than the in vitro half-life (Koelsch et al., 2008). In
addition, studies following patients who are vaccinated suggest that
there are bursts of replication that occur at times of hyper-immune
activation (Shiu et al., 2009). Arguments against this theory include
the lack of viral evolution in a subset of patients on HAART (Dahl and
Palmer, 2009; Joos et al., 2008; Shen and Siliciano, 2008) and the fact
that intensiﬁcation regimens appear to have no effect on reservoir size
(Dinoso et al., 2009a; Gandhi et al., 2010; Jones et al., 2009). In
addition, it is hard to imagine how a constant level of latently infected
cells would be maintained by ongoing replication (Chomont et al.,
2009; Koelsch et al., 2008; Siliciano et al., 2003).
However, it is also possible that different mechanisms of
persistence occur in different subsets and that many mechanisms of
persistence may be maintaining the reservoir. For example, work by
Chomont et al. showed that different HIV infected CD4+ T cell subsets
were maintained differently: transitional memory cells were main-
tained through IL-7 mediated homeostatic proliferation while
infected central memory cells are maintained through cell survival
and low level antigen-driven proliferation (Chomont et al., 2009).
Why we should study models of latency
How reservoirs are formed and maintained remain unanswered
questions. One way to answer these questions is by studying models
of HIV latency. In addition, we may be able to use these models to ﬁnd
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strategies (Trono et al., 2010; Williams and Greene, 2005). Several
strategies have been proposed (Coiras et al., 2009; Colin and Van Lint,
2009; Dahl and Palmer, 2009; Margolis, 2010). These include
intensiﬁcation regimens under the assumption that limiting drug
levels may allow low levels of HIV replication: supplying more anti-
retrovirals would potentially eliminate the low level of replication.
These strategies have been largely disappointing because the size of
the reservoir does not appear to be changed by the addition of more
drugs or a higher concentration of drugs as mentioned earlier (Dinoso
et al., 2009b; Gandhi et al., 2010; Jones et al., 2009). However, it may
be that intensiﬁcation does not deliver sufﬁcient drug to the site(s) of
ongoing replication (Di Mascio et al., 2009).
A second strategy has been to stimulate latently infected cells so
they produce virions and then become susceptible to viral toxicity and
immune clearance. Early attempts to stimulate latent virus into
productive infectionwere abandoned because of toxic reactions to the
activation steps (Prins et al., 1999; van Praag et al., 2001). Thus, it
would be ideal to identify methods of stimulating reservoirs without
causing global T cell activation (Margolis, 2010). Several groups are
already attempting to identify such methods (Archin et al., 2009;
Brooks et al., 2003b; Yang et al., 2009a; Yang et al., 2009b). Models of
latency are most useful for this task. Stimulation and intensiﬁcation
strategies may be most effective when combined (Lehrman et al.,
2005).
A third strategy, which has not been pursued for removing the
viral reservoir, is to stimulate the immune response to clear latently
infected cells. This strategy has not been utilized for this purpose
because it is unclear to what extent latently infected cells express HIV
proteins, as previously mentioned. Therefore, vaccine generated CTL
and other immune strategies could be tested in latent models to see if
the immune response has an effect on the level of latently infected
cells. Even if latently infected cells do not express sufﬁcient protein to
be subject to CTL, stimulating a CTL response may be effective if
combined with methods to stimulate cells to produce infectious virus.
Current Models of HIV Latency
In vivo models in primates
SIV has commonly served as a model for HIV infection in non-
human primates. However, the lack of effective HAART models in
these animals has made it more difﬁcult to model HIV infected
patients on therapy. However, recent advances in modeling HAART
therapy in non-human primates have made studying latency in this
system easier and more effective (Dinoso et al., 2009b; North et al.,
2010; Shen et al., 2007; Shen et al., 2003). Shen et al. used two reverse
transcriptase inhibitors to model HAART in pig-tailed macaques and
lowered viral loads to levels similar to those found in patients on
HAART (Shen et al., 2003). Using this system, Shen et al. found that
replication competent virus was recoverable from the lymph nodes of
treated animals (Shen et al., 2003). In addition, they found
thymocytes were not a substantial reservoir for SIV in their model
(Shen et al., 2003). Later, Shen et al. used this model to study
alternative activation pathways for SIV reactivation involving CD2
(Shen et al., 2007). More recently, HAART therapy has been modeled
using a larger number and variety of anti-retrovirals in non-human
primates (Dinoso et al., 2009b; North et al., 2010). In these animals,
Dinoso et al. found that the number of resting cells harboring
replication competent virus was greatly reduced in HAART treated
animals and that the frequency of these cells was similar in lymph
nodes, spleen and PBMC (Dinoso et al., 2009b). In addition, North et al.
modeled HAART therapy in rhesus macaques using a RT-SHIV virus
with a reverse transcriptase from HIV, making the virus susceptible to
nonnucleoside RT inhibitors (NNRTIs) (North et al., 2010). In this
study, viral DNA and RNA levels were measured in treated animals inlymphoid tissue, neurological tissue, the GI tract, reproductive tissues
and several other organs (North et al., 2010). Importantly, resting CD4+
T cells harbored viral DNA but little RNA in PBMC, lymph nodes, spleen,
and the jejunum, consistent with the presence of a latent HIV reservoir
in these locations.
Nonhuman primate models have several advantages for studying
latency. These models allow the study of several different organ
systems. This is important since some studies provide evidence that
the viral sequences responsible for residual viremia are often not
detectable within PBMC from blood (Bailey et al., 2006; Brennan et al.,
2009). In addition, nonhuman primates have immune responses that
resemble human immune responses. However, nonhuman primate
models are expensive and require several months for a single
experiment. Additionally, while HIV remains latent in humans for
several years, this phase is contracted in nonhuman primates to
months. Finally, nonhuman primate models utilize SIV, which does
differ fromHIV and these differencesmay affect the latency properties
of SIV as compared to HIV.In vivo models in mice
Humanized mouse models (transplanted with either human
tissues or stem cells) are also becoming popular models for the
study of HIV latency. One of the ﬁrst described was the SCID-hu (Thy/
Liv) model (Brooks et al., 2001; Kaneshima et al., 1994; Rabin et al.,
1996). Here, severe combined immunodeﬁcient CB17-scid (SCID)
mice are transplanted with human fetal thymus and liver tissues
under the kidney capsule (Brooks et al., 2001). This model has been
used to study latency in several papers revealing the importance of
protein kinase C and NFAT pathways in activating HIV production in
latent cells (Brooks et al., 2003a) as well as the ability of anti-HIV
immunotoxin to deplete the reservoir after stimulating the latent
reservoir with IL-7 (Brooks et al., 2003b). This mouse model has
several advantages. Transplanting human thymic implants can
recapitulate human thymopoiesis, thus allowing the study of thymic
infection (Brooks et al., 2001). In addition, because most of the cells
generated in this model are naïve, naïve cell infection can also be
studied. However, there are also disadvantages to this model. Because
there is no systemic reconstitution of the immune system, sites of
potential infection are limited. In particular, mucosal tissues that can
be infected by HIV are lacking. In addition, since most of the cells are
naïve, memory cell infection is more difﬁcult to study. However,
advances in humanized mouse models have eliminated some of these
concerns. Both NOD/SCID BLT mice and Rag2-/-γc-/- mice better
reconstitute the human immune system as well as mucosal tissues
suitable for HIV infection (Denton and Garcia, 2009; Van Duyne et al.,
2009). The ﬁrst model transplants bonemarrow, liver, and the thymus
under the kidney capsule. Transplantation of the liver and thymus
enhances the reconstitution of the immune system. The Rag2-/-γc-/-
mice also allow enhanced reconstitution of the human immune
system within the mouse after bone marrow transplantation
following irradiation. In addition, it has been shown that these mice
can be infected for up to a year chronically (Berges et al., 2010).
Therefore, these new mice models can lead to more effective studies
of HIV latency than previous models.In vitro Models (Table 2)
In vitro models of HIV latency have several advantages over their
in vivo counterparts. They are easier and have faster readouts than
in vivo experiments. In vitro models are also ideal for biochemical
screens in order to test for potential therapeutics. Concentrated
efforts have been made to develop successful in vitro models for HIV
latency.
Table 2
Different in vitro models of HIV latency.
Model Description Naïve Central Memory Effector Memory In vitro stimulation Enough cell for screening Longevity
Burke/Zack Thymoctyes Yesa Yes Yes Yes No No
Sahu/Cloyd &
Tyagi/Karn
Stimulated na ve cells cultured
on feeder cells
No Yesa No Yes No Yes
Marini/Romerio DC activated cells cultured in IL-7 No Yesa No Yes No Yes
Bosque/Planelles Na ve cells primed Cultured in IL-2 No Yesa Yes Yes Yes Yes
Yang/Siliciano BCL-2 transduced cells No No Yesa Yes Yes Yes
Swiggard/O'Dohertyb Direct infection resting cells Yes Yes Yes No No No
Saleh/Lewinb CCR7 stimulation resting cells Yes Yes Yes Yes Yes No
a=majority of population.
b=All infections occurred after activation except Swiggard and Saleh.
Different in vitromodels of latency are listed by the authors who developed them, followed by a description of the model and the types of cells present in the system (yes represents
the presence of the cell in the system). Whether the system utilizes in vitro stimulation before infection is also listed. Finally, the amount of cells produced is compared followed by
whether or not the system can be maintained over long periods of time (longevity).
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Many latency models have used cell lines, which have provided
useful information (Han et al., 2007; Jordan et al., 2003; Kutsch et al.,
2003). We will focus exclusively on latency models using primary
cells (Table 2), since they more accurately reﬂect in vivo latency.
Thymocyte model
Burke et al. developed an in vitromodel based on the mousemodel
previously described by the lab, where CD4+CD8+ thymocytes are
infected with an HIV based reporter virus, lacking or containing
mutated several structural and accessory HIV genes (Burke et al.,
2007). Cells are then cultured in the presence of IL-2 and IL-4. Using
this model, Burke et al. found that NF-κβ signaling is important for
HIV reactivation (Burke et al., 2007). Because the model results in
mostly naïve CD4+ T cell infection, it makes it harder to study latency
in memory cells, which has been shown to be a larger part of the HIV
reservoir in most patients (Brenchley et al., 2004; Chomont et al.,
2009; Chun et al., 1997a; Ostrowski et al., 1999). However, given that
many models ignore naïve infection, this model provides a method to
study this important cell type. Furthermore, the model does allow for
thymocyte infection to be modeled in vitro. Other disadvantages
include the use of a mutated reporter virus, which may not accurately
reﬂect wild type HIV latency, the limited number of cells generated,
and the short timeframe of the model (approximately 10 days).
Activated CD4+ T cell models
Others have activated CD4+ T cells, infected them with an HIV
derived vector, and then maintained the cells on a feeder cell line for
months (Sahu et al., 2006; Tyagi et al., 2010). Tyagi et al. used this
model to describe epigenetic silencing and low P-TEFb levels
contributing to HIV latency (Tyagi et al., 2010). This model generates
a large number of cells that can bemaintained for long periods of time.
However, culturing activated cells on a feeder cell line leads to a
relatively homogeneous population of central memory cells (Tyagi
et al., 2010), which prevents the study of other important cell types
including transitional memory cells, which are also a major part of the
reservoir (Chomont et al., 2009). In addition, the cells are not
completely resting in nature, expressing higher levels of CD25 and
Ki67 (Tyagi et al., 2010). Once again the use of mutated HIVmay affect
the latent behavior of the virus.
Marini et al. used AG-loaded dendritic cells to stimulate primary
naïve CD4+ T cells for wild type infection, before culturing the cells in
the presence of IL-7 to generate latent cells (Marini et al., 2008). Using
this model, Marini et al. observed higher cell death rates with infected
cells but not uninfected cells upon secondary stimulation (Marini
et al., 2008). An advantage of this systemwas the use of wild type HIV.
In addition, the model may be appropriate for examining the effect ofHIV reactivation on cell death. Some disadvantages of this system
include the requirement for IL-7, which has been shown to reactivate
HIV in latently infected cells (Scripture-Adams et al., 2002; Wang
et al., 2005), as well as the number of cells generated by the system
(~20% viable cells) (Marini et al., 2008). Additionally, the cells take on
a central memory phenotype, which has the same disadvantages as
mentioned above.
Bosque et al. developed a model of HIV latency where naïve CD4+
T cells are activated and primed to a Th1 or Th2 phenotype, or left
unprimed for a central memory phenotype (Bosque and Planelles,
2011; Bosque and Planelles, 2009). The cells are then infected with
env-deﬁcient HIV pseudotyped with HIV env and cultured in the
presence of IL-2 (Bosque and Planelles, 2009). This model generates
large numbers of latently infected cells with several different
phenotypes, an important advantage for drug screening compared
to the previous models. However, the model does not allow the study
of naïve cells, which play a role in the HIV reservoir in patients (Blaak
et al., 2000; Heeregrave et al., 2009; Ostrowski et al., 1999; Pierson
et al., 2000a; Wightman et al., 2010). In addition, because of the
activation step, the cells express lower levels of CCR5, making it
difﬁcult to study R5-tropic HIV.
Recently, Yang et al. described an HIV latency model usable for
drug screening where primary cells are transduced with a viral vector
encoding BCL2, an anti-apoptotic protein downstream of IL-7
signaling (Yang et al., 2009b). This allows the cells to remain long-
lived without the need for cytokine stimulation. After culturing the
cells for several weeks, the cells are then infected with HIVmutated in
several genes to minimize cell death due to viral protein toxicity
(Yang et al., 2009b). This model generates enough cells for drug
screening, an essential task for developing therapeutics to remove the
latent reservoir. However, the model generates effector memory cells
(Yang et al., 2009b), which are not the major reservoir of HIV in
patients (Chomont et al., 2009). In addition, mutated HIV may not
accurately represent wild type HIV latency.
Resting CD4+ T cell model
A ﬁnal in vitro model of HIV latency is the direct infection of
primary resting CD4+ T cells described by our lab (Agosto et al., 2007;
O'Doherty et al., 2000; Swiggard et al., 2005). Here, resting cells are
spinoculated with wild type HIV, resulting in latently infected cells.
There has been some controversy with regards to the susceptibility of
resting cells to direct infection, which will be discussed later. This
direct infection model avoids any activation step and thus maintains
cells as they exist in the body, allowing accurate study of every cell
phenotype. In addition, the model uses wild type HIV, which will
reﬂect the latency properties of virus found in vivo. However, limiting
cell numbers is an issue with this model since no activation steps exist
to expand cell number. In addition, the longevity of this model is
relatively short without culturing the cells in low levels of cytokines
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model, described by the Lewin lab, involves stimulating cells with the
CCR7 ligands CCL19 and CCL21 to enhance infection (Saleh et al.,
2007). However, these ligands will not affect each T cell subset
similarly since some subsets (naïve and central memory) express
CCR7, while others (transitional and effector memory cells) do not
(Chomont et al., 2009). The Lewin lab also reported stimulating CD4+
T cells with other ligands including CXCL10 and CCL20 (Cameron
et al., 2010). These stimuli appear to enhance HIV infection and cell
viability. Lewin and colleagues report that these stimuli enhance
integration; however, we ﬁnd these cytokines unnecessary for resting
cell infection. The mechanism of these cytokines for enhancing
cellular latency is the subject of current work and a better
understanding of these models is an important area of research.
Unresolved issues in resting CD4+ T cell infection
Signaling
One important issue that still needs to be resolved regarding
resting cell infection is the role of cell signaling in infection. This is
important to understand because if signaling enhances infection,
inhibition of signaling may decrease it and could even be used
therapeutically. Furthermore, utilizing signaling may enable us to
improve our in vitromodels. It has become clear that HIV does signal T
cells both through CD4 and through the co-receptor (Briant et al.,
1996; Cicala et al., 2006; Popik and Pitha, 2000; Stantchev and Broder,
2001). This HIV mediated signaling may affect infection, as some
reports show that co-receptor signaling enhances infection, perhaps
at the level of nuclear import by overcoming a cortical actin barrier
(Yoder et al., 2008; Yu et al., 2009). Signaling may also play a role by
enhancing endocytosis, which may facilitate fusion (Miyauchi et al.,
2009). In addition, chemokines and cytokines that are present in
plasma may also play a role in HIV infection, since several reports
suggest some chemokines enhance infection, also at the level of
nuclear import (Cameron et al., 2010; Saleh et al., 2007). These results
are controversial because we ﬁnd that nuclear import occurs without
the need for additional chemokines and with apparently similar
efﬁciency as in activated cells, where the cortical actin barrier does not
exist (Dai et al., 2009). This discrepancy may be due to variable levels
of chemokines and cytokines in serum. In addition, our experiments
are single round infection experiments while other studies were not
(Cameron et al., 2010; Saleh et al., 2007; Yoder et al., 2008; Yu et al.,
2009), and so potentially multiple rounds of infection may have
occurred which could amplify infection, making a small effect more
readily detectable. Additionally, some reports (Yoder et al., 2008)
activated cells before examining their infection levels, possibly
altering their results.
Discrepancies in the resting CD4+ T cell model of HIV latency
There has been some confusion regarding the susceptibility of
resting cells to direct HIV infection. Direct inoculation of resting CD4+
T cells has only recently been considered a valid model for studying
HIV latency in large part because these cells were deemed completely
resistant to HIV integration (Yamashita and Emerman, 2006). A
historical accounting of the discoveries leading to our current
understanding of resting T cell infection, as well as the restriction
factors involved in resting cell infection (not covered here), was
recently reviewed (Vatakis et al., 2010). In particular, several factors
played a role leading to the misconception that resting cells were not
susceptible to HIV. These factors include slower kinetics in this cell
type as well as the common use of VSV-G pseudotyped particles.
When these factors were addressed, HIV was shown to infect resting
cells.The ﬁrst discrepancy was due to a difference in kinetics. Pioneering
experiments showed that the efﬁciency of reverse transcription in
resting CD4+ T cells is much lower than in activated T cells (Zack et al.,
1990). These studies concentrated onmonitoring intermediates at early
timepointswhenhugedifferences between resting and activatedCD4+
T cells are apparent. However, as studies were performed with longer
time courses (Spina et al., 1995), it became clear that HIV can directly
integrate into resting CD4+T cells and that this leads to latent infection,
at least in vitro (Agosto et al., 2007; Dai et al., 2009; Hladik et al., 2007;
Plesa et al., 2007; Swiggard et al., 2005; Vatakis et al., 2007).Notably, it is
necessary to assay for these intermediates 2–3 days after infection to
detect signiﬁcant levels in resting cells,while these intermediates canbe
detected within hours of infection of activated CD4+ T cells.
Quantitatively, resting CD4+ T cells have less integrated HIV DNA
than activated cells after in vitro inoculation. Somegroups (Vatakis et al.,
2007) see larger differences between resting and activated cells than
other groups (Plesa et al., 2007). The magnitude of the difference could
be related to the level of activation of the cells. Perhaps the most
important difference in infection in these cell types is that resting cells
produce no detectable infectious virus compared to activated cells,
whichproduce abundant infectious virions. Overall, discrepancies in the
literature describing resting cell infection can in large part be resolved
by considering kinetics of infection.
The second discrepancy was due to the use of VSV-G pseudotypes.
VSV-G is frequently used to pseudotype HIV in order to enhance
infection since the VSV-G receptor is thought to be ubiquitous. When
these pseudotyped particles were unable to infect resting CD4+
T cells, it was assumed that the barrierwas toHIV infection (Dardalhon
et al., 2001;Unutmaz et al., 1999; Verhoeyen et al., 2003). However,we
and others recently showed that the barrier to resting cell infection is
to VSV-G, not HIV (Agosto et al., 2009; Frecha et al., 2008; Yu et al.,
2009). We have shown that VSV-G cannot mediate fusion to resting
CD4+ T cells because of an endocytosis deﬁciency that is overcome
when cells enter the cell cycle (Agosto et al., 2009; Pace et al., 2011).
Thus, the use of VSV-G pseudotypes and short time courses
together may explain why it seemed necessary for cells to enter G1b
of the cell cycle for HIV infection of CD4+ T cells.
These discoveries illustrate how using non wild-type HIV or
in vitro stimulated cells can have profound effects on the study of HIV
and the interpretation of those studies. Similarly, differences in the
experimental approach of latency models (activation steps, and viral
envelopes used) can impact overall ﬁndings. While there are distinct
advantages to every model, a clear advantage of direct inoculation
without stimulation is the fact that the cells will more closely parallel
cells found in vivo.
Conclusion
Overall, there are several different in vitromodels for studying HIV
latency using primary cells each with advantages and disadvantages.
Some excel as models of naïve cell infection and infection during
thymopoiesis (Burke et al., 2007). Others have already proven to be
useful tools for drug screenings (Bosque and Planelles, 2009; Yang
et al., 2009b), while some models best reﬂect physiological cells and
events (Cameron et al., 2010; Saleh et al., 2007; Swiggard et al., 2005).
While each model alone may not be sufﬁcient to capture the
properties of latent HIV infection, together these models can function
to study many of the important characteristics of HIV latency
including reservoir formation and persistence.
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